Fig. 5.

Graphical representation of currently recommended therapeutic agents depending on the clinical condition.Top shows the natural course of COVID-19 infection. The symptomatic phase occurs after incubation at >20 % infection. Out of patients in critical condition even around 50 % die. Bottom shows suggested therapeutic interventions depending on the course of the disease 80 % – mild course of the disease; neutralizing antibodies recommended if high risk of disease progression. 15 % - severe course of the disease; dexamethasone and remdesivir recommended for patients with SpO₂ ≤94 % on room air; if rapidly increasing oxygen need and systemic inflammation – consider baricitinib or tocilizumab. 5% - acute respiratory distress syndrome (ARDS) or multi-organ failure develops; use dexamethasone and consider tocilizumab.